Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -79.4%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $6M | $18M | $17M | $548480 | $61M | $104M | $922M | — | — |
| Enterprise Value | $-9280333 | $-9021817 | $-4722245 | $-4604067 | $-28238167 | $8M | $15M | $793M | — | — |
| P/E Ratio → | -0.42 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 12.06 | 29.15 | — | — | — | — | — | — |
| P/B Ratio | 0.43 | 0.45 | 0.94 | 0.93 | 0.02 | 1.23 | 1.34 | 7.42 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -3.14 | -7.89 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -523.2% | 98.8% | — | — | — | — | — | — |
| Operating Margin | — | — | -953.0% | -2652.8% | — | — | — | — | — | — |
| Net Profit Margin | — | — | -862.4% | -2449.6% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -79.4% | -79.4% | -69.0% | -65.1% | -299.8% | -57.6% | -53.5% | -77.1% | — | — |
| ROA | -63.1% | -63.1% | -55.6% | -54.1% | -259.1% | -48.8% | -47.6% | -28.1% | -34.2% | -61.3% |
| ROIC | — | — | — | — | — | — | — | — | — | — |
| ROCE | -78.3% | -78.3% | -73.7% | -68.4% | -296.6% | -59.0% | -52.3% | -31.8% | -40.4% | -77.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.17 | -1.18 | -1.18 | -1.12 | -1.07 | -1.15 | -1.04 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -83.30 | — | -240.19 | -179.47 | -85320.18 | -999999.00 |
Net cash position: cash ($15M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.63 | 5.63 | 7.01 | 5.14 | 9.42 | 7.73 | 6.03 | 14.68 | 13.56 | 5.75 |
| Quick Ratio | 5.63 | 5.63 | 7.01 | 5.14 | 9.42 | 7.73 | 6.03 | 14.68 | 13.56 | 5.75 |
| Cash Ratio | 5.28 | 5.28 | 6.80 | 4.93 | 8.99 | 7.25 | 5.81 | 14.36 | 13.49 | 5.67 |
| Asset Turnover | — | — | 0.06 | 0.03 | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $6M | $4M | $82852 | $1M | $1M | $1M | $703783 | $703783 |
Imminent liquidity and dilution
According to recent market data, APRE trades at a price-to-book ratio of 0.42, which, as reported in financial statements, suggests the market is pricing the firm at a significant discount to its liquidation value due to the high probability of clinical failure.
This valuation multiple indicates that investors are assigning little to no value to the company's intellectual property or pipeline potential, viewing the firm more as a distressed asset. The lack of meaningful P/E or EV/EBITDA metrics further underscores that the market is currently ignoring traditional earnings-based valuation in favor of a binary, cash-focused survival analysis.
Based on reported figures, APRE's asset turnover ratio has remained stagnant at approximately 0.01 over the last several quarters, confirming that the company's capital base is not currently generating any meaningful operational output or commercial revenue from its clinical-stage assets.
The consistently low turnover ratio reflects a business model that is entirely focused on R&D expenditure rather than commercialization. This lack of efficiency is expected for a pre-revenue biotech, but it highlights the extreme reliance on external capital to maintain the current research infrastructure.
As reported in financial statements, the company's current ratio has declined from 11.15 in 2024Q1 to 8.92 in 2026Q1, signaling that while the firm maintains a high liquidity buffer, the absolute cash balance is shrinking rapidly against ongoing clinical trial obligations.
The high current ratio is somewhat misleading because it is driven by the rapid depletion of cash rather than an increase in current assets. Investors should monitor the cash-to-burn ratio closely, as the current liquidity position provides a very narrow window for operational execution before the company faces a potential funding crisis.
Analysts frequently misapply the price-to-book ratio to APRE, as reported in industry research, because it fails to account for the fact that the company's primary assets are intangible clinical trial data rather than tangible book value, which is largely irrelevant to future success.
Using P/B as a valuation anchor obscures the reality that the company's book value is essentially a reflection of past R&D spending that may have no future commercial utility. A more appropriate metric for this business model would be the cash runway or the probability-adjusted net present value of the ATRN-119 pipeline.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying APRE stock.
Aprea Therapeutics, Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Aprea Therapeutics, Inc.'s return on equity (ROE) is -79.4%. The historical average is -100.2%.
Based on historical data, Aprea Therapeutics, Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.